Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
European journal of heart failure, 2019-10, Vol.21 (10), p.1270-1278 [Peer Reviewed Journal]Attribution - NonCommercial ;ISSN: 1388-9842 ;EISSN: 1879-0844 ;DOI: 10.1002/ejhf.1536 ;PMID: 31584231
Digital Resources/Online E-Resources